Business Strategy

Business Model

Preclinical development

Aptahem has brought together a strong team of experts to take the development of Apta-1 to clinical Phase I/II. However, assuming that sufficient data is gathered on effect, toxicity and mechanism of action to attract interest, the initial goal is to identify a licencee partner or investor at the pre-clinical stage that is able to continue development through the latter, more costly clinical studies in Phase II/III and on to market launch. Aptahem’s business structure is flexible and cost efficient, with project management and scientific expertise within the company and co-operation with individual specialists and consultants brought in when needed. The contract research organisations and academic research groups with which Aptahem works are based worldwide, and are selected by competence, experience and cost structure.

Apta-1 is currently in the pre-clinical phase, and non-confidential discussions are being conducted with potential licencees and/or buyers.

Commercial Partnership

Interest from established pharmaceutical companies

Aptahem is in regular discussions with pharmaceutical companies with a view to finding a suitable project partner to potentially finance latter clinical studies and potential market launch. Considerable interest exists in Aptahem’s leading drug candidate, Apta-1, from pharmaceutical companies and other investors. Various stakeholders are monitoring the progress of Apta-1 very closely as the next milestone is to finalise pre-clinical trials with the aim of demonstrating the substance’s safety profile and thereby obtain approval to conduct the first-in-human studies.

Licensing

Creative licensing agreements

Taking a drug candidate from idea to market launch usually takes a long time, and is highly costly. To reduce drug development times, well-established pharmaceutical companies need to externally develop promising products outside their own, in some cases non-existent, R&D departments. Consequently, most of the larger pharmaceutical companies are out looking for potential projects that match their product portfolio to license or invest in development projects that have cleared the initial detection phase. How such an agreement looks depends on many different factors, and is proceeded by thorough due diligence and discussions. For a company such as Aptahem, this can mean that a development project can be entirely licensed to a larger pharmaceutical company, or that a co-operation is entered into whereby continued development work to market launch is financed by the pharmaceutical company.